best glp-1 for pcos medications are not approved by the Food and Drug Administration to treat polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome in 2026. Because the use is off-label What You Must Know About

Mild tenderness or temporary bruising at the insertion site may occur

On May 5, 2026, one of those nominators clarified its position

What Research Says About Weight Loss Results In a 68-week clinical trial of Wegovy, participants lost an average of 15% of their body weight compared to just 2% in the placebo group

[1] [4] This means if your usual injection day is Saturday, you can safely administer your dose anytime between Thursday and Monday without compromising treatment efficacy or safety

To further verify those findings, flow cytometry of the bone marrow differentiated cells was performed

Participants on semaglutide lost an average of nearly 15% of body weight, while those on the highest dose of tirzepatide lost more than 20%, both over roughly 16 to 17 months of treatment